Morphine Sulfate ER
Total Payments
$1.3M
Transactions
116
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $90,869 | 12 | 0 |
| 2019 | $1.1M | 75 | 0 |
| 2018 | $151,533 | 29 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 116 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Morphine Pediatric Study | Hikma Pharmaceuticals USA | $1.2M | 0 |
| Morphine Pediatric Study | West-Ward Pharmaceuticals | $151,533 | 0 |
Top Doctors Receiving Payments for Morphine Sulfate ER
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Little Rock, AR | $1.3M | 116 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $1.2M
- West-Ward Pharmaceuticals $151,533
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 0
- Transactions 116
About Morphine Sulfate ER
Morphine Sulfate ER is a drug associated with $1.3M in payments to 0 healthcare providers, recorded across 116 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2018 to 2020. In 2020, $90,869 was paid across 12 transactions to 0 doctors.
The most common payment nature for Morphine Sulfate ER is "Unspecified" ($1.3M, 100.0% of total).
Morphine Sulfate ER is associated with 2 research studies, including "Morphine Pediatric Study" ($1.2M).